Cosi C, Altar A C, Wood P L
Research Department, Ciba-Geigy Corporation, Summit, NJ 07901.
Eur J Pharmacol. 1989 Jun 20;165(2-3):209-14. doi: 10.1016/0014-2999(89)90714-0.
The effect of sulfated cholecystokinin (CCK-8S) on acetylcholine turnover (TRACh) and dopamine (DA) release in the rat cerebral cortex and striatum was studied in unanaesthetized animals in vivo. CCK-8S (1 mg/kg s.c.) decreased TRACh in the fronto-parietal cortex but not in the striatum. This effect was prevented by peripheral (10 mg/kg i.p.) but not central (1 microgram i.v.t.) administration of the peripheral CCK receptor antagonist CR 1409. In a separate study, CCK-8S decreased 3-methoxytyramine (3-MT) levels (an index of DA release) in the fronto-parietal cortex and in the striatum. CR 1409 appeared to have a partial agonist action, reducing cortical and striatal 3-MT levels, and only partially reversing the effect of CCK-8S in the striatum. These data indicate that peripheral administration of CCK-8S decrease TRACh in the cortex but not in the striatum and that this action is mediated by peripheral-type CCK receptors possibly located outside the CNS. CCK-8S also reduces DA release in the cortex and in the striatum, and this effect appears to be mediated by a mechanism of action different from that modulating cortical TRACh.
在未麻醉的动物体内，研究了硫酸化胆囊收缩素（CCK-8S）对大鼠大脑皮层和纹状体中乙酰胆碱周转率（TRACh）及多巴胺（DA）释放的影响。CCK-8S（1毫克/千克，皮下注射）可降低额顶叶皮层中的TRACh，但对纹状体无此作用。外周注射（10毫克/千克，腹腔注射）外周CCK受体拮抗剂CR 1409可阻止此效应，而中枢注射（1微克，脑室内注射）则不能。在另一项研究中，CCK-8S可降低额顶叶皮层和纹状体中3-甲氧基酪胺（3-MT）的水平（DA释放的指标）。CR 1409似乎具有部分激动剂作用，可降低皮层和纹状体中3-MT的水平，且仅部分逆转CCK-8S在纹状体中的作用。这些数据表明，外周给予CCK-8S可降低皮层而非纹状体中的TRACh，且此作用由可能位于中枢神经系统外的外周型CCK受体介导。CCK-8S还可降低皮层和纹状体中的DA释放，且此效应似乎由不同于调节皮层TRACh的作用机制介导。
